Revelation Biosciences, Inc. (NASDAQ:REVB) Sees Significant Decrease in Short Interest

Revelation Biosciences, Inc. (NASDAQ:REVB) was the recipient of a significant drop in short interest in the month of December. As of December 15th, there was short interest totalling 43,700 shares, a drop of 65.3% from the November 30th total of 125,800 shares. Based on an average daily trading volume, of 1,060,000 shares, the days-to-cover ratio is presently 0.0 days. Currently, 0.5% of the shares of the company are short sold.

Revelation Biosciences Stock Up 15.2 %

NASDAQ:REVB traded up $0.05 on Thursday, reaching $0.35. 2,558,001 shares of the company’s stock traded hands, compared to its average volume of 955,570. The firm has a market cap of $1.49 million, a PE ratio of -0.02 and a beta of 0.15. The stock has a 50-day simple moving average of $0.68 and a 200-day simple moving average of $1.12. Revelation Biosciences has a 12 month low of $0.28 and a 12 month high of $25.26.

About Revelation Biosciences

Revelation Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease.